Pharma Technology Focus: Open-Inhale-Close Multidose DPI Platform
Developing dry powder inhalers that balance patient usability, robust performance, and commercial scale manufacturability remains a significant challenge for pharmaceutical companies. In this Pharma Technology Focus Company Insight, Phillips Medisize highlights its Open Inhale Close (OIC) dry powder inhaler platform, a pre-metered, multidose DPI designed to accelerate development timelines while reducing technical, regulatory and scale up risk.
The OIC platform combines an intuitive three step user interface with advanced blister technology, delivering strong moisture protection, in use stability, and formulation flexibility. With multiple dosing and indexing options, and readiness for future enhancements such as digital adherence sensing, the platform is engineered to support a wide range of indications and lifecycle strategies. Backed by proven performance, human factors validation, and scalable manufacturing, Phillips Medisize enables pharmaceutical partners to enter and compete in the DPI market with greater confidence and speed.
